CD33 and myelodysplastic syndrome: Particularly, the activity of gemtuzumab, and PBD-conjugated ADCs targeting CD33 and CD123 was found to be significantly decreased in MDS/AML cell lines compared to AML cell lines derived from de novo/ TP53-wild type AML.